BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38376007)

  • 1. Heart failure during acute coronary syndrome and the long-term cancer risk: the ABC-9 Study on heart disease.
    Mahmoud HT; Berton G; Cordiano R; Palmieri R; Merotto D; Menegon F
    ESC Heart Fail; 2024 Jun; 11(3):1389-1399. PubMed ID: 38376007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings.
    Agra Bermejo R; Cordero A; García-Acuña JM; Gómez Otero I; Varela Román A; Martínez Á; Álvarez Rodríguez L; Abou-Jokh C; Rodríguez-Mañero M; Cid Álvarez B; López-Palop R; Carrillo P; González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2018 Oct; 71(10):820-828. PubMed ID: 29249471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial.
    Mukherjee JT; Beshansky JR; Ruthazer R; Alkofide H; Ray M; Kent D; Manning WJ; Huggins GS; Selker HP
    Cardiovasc Ultrasound; 2016 Aug; 14(1):29. PubMed ID: 27488569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
    Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure in women and men during acute coronary syndrome and long-term cardiovascular mortality (the ABC-3* Study on Heart Disease) (*Adria, Bassano, Conegliano, and Padova Hospitals).
    Berton G; Cordiano R; Cavuto F; Bagato F; Pellegrinet M; Cati A
    Int J Cardiol; 2016 Oct; 220():538-43. PubMed ID: 27390984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome.
    Shin SH; Claggett B; Pfeffer MA; Skali H; Liu J; Aguilar D; Diaz R; Dickstein K; Gerstein HC; Køber LV; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Tardif JC; Solomon SD;
    Eur J Heart Fail; 2020 Jul; 22(7):1133-1143. PubMed ID: 32212368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction.
    Citro R; Radano I; Parodi G; Di Vece D; Zito C; Novo G; Provenza G; Bellino M; Prota C; Silverio A; Antonini-Canterin F; Rigo F; Vriz O; Galasso G; Bossone E; Salerno-Uriarte J; Piscione F
    Eur J Heart Fail; 2019 Jun; 21(6):781-789. PubMed ID: 30714660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender Differences in Left Ventricular Ejection Fraction and Outcomes Among Patients Hospitalized for Acute Decompensated Heart Failure.
    Kajimoto K; Minami Y; Sato N; Otsubo S; Kasanuki H;
    Am J Cardiol; 2017 May; 119(10):1623-1630. PubMed ID: 28325570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial Strain for Identification of β-Blocker Responders in Heart Failure with Preserved Ejection Fraction.
    Park JJ; Choi HM; Hwang IC; Park JB; Park JH; Cho GY
    J Am Soc Echocardiogr; 2019 Nov; 32(11):1462-1469.e8. PubMed ID: 31540679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of diabetes on mortality and rehospitalization in acute heart failure patients stratified by ejection fraction.
    Al-Jarallah M; Rajan R; Al-Zakwani I; Dashti R; Bulbanat B; Ridha M; Sulaiman K; Alsheikh-Ali AA; Panduranga P; AlHabib KF; Al Suwaidi J; Al-Mahmeed W; AlFaleh H; Elasfar A; Al-Motarreb A; Bazargani N; Asaad N; Amin H
    ESC Heart Fail; 2020 Feb; 7(1):297-305. PubMed ID: 31825180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
    Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction.
    Cespón-Fernández M; Raposeiras-Roubín S; Abu-Assi E; Pousa IM; Queija BC; Paz RJC; Erquicia PD; Rodríguez LMD; Rodríguez EL; Busto MC; Barbeira SF; Romo AÍ
    Angiology; 2020 Nov; 71(10):886-893. PubMed ID: 32757765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades.
    Vasan RS; Xanthakis V; Lyass A; Andersson C; Tsao C; Cheng S; Aragam J; Benjamin EJ; Larson MG
    JACC Cardiovasc Imaging; 2018 Jan; 11(1):1-11. PubMed ID: 28917679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of mineralocorticoid receptor antagonists treatment after acute coronary syndrome in the real world: A propensity score matching analysis.
    Agra-Bermejo R; Cordero A; Rodríguez-Mañero M; García Acuña JM; Álvarez Álvarez B; Martínez Á; Álvarez Rodríguez L; Abou-Jokh C; Cid Álvarez B; González-Juanatey JR
    Eur Heart J Acute Cardiovasc Care; 2019 Oct; 8(7):652-659. PubMed ID: 30117745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incident Heart Failure and Long-Term Risk for Venous Thromboembolism.
    Fanola CL; Norby FL; Shah AM; Chang PP; Lutsey PL; Rosamond WD; Cushman M; Folsom AR
    J Am Coll Cardiol; 2020 Jan; 75(2):148-158. PubMed ID: 31948643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
    Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
    ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and impact of cardiorenal anaemia syndrome on all-cause mortality in acute heart failure patients stratified by left ventricular ejection fraction in the Middle East.
    Al-Jarallah M; Rajan R; Al-Zakwani I; Dashti R; Bulbanat B; Sulaiman K; Alsheikh-Ali AA; Panduranga P; AlHabib KF; Al Suwaidi J; Al-Mahmeed W; AlFaleh H; Elasfar A; Al-Motarreb A; Ridha M; Bazargani N; Asaad N; Amin H
    ESC Heart Fail; 2019 Feb; 6(1):103-110. PubMed ID: 30315634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.